Welcome to our dedicated page for CS Diagnostics SEC filings (Ticker: CSDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CS Diagnostics Corp. (CSDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it develops and commercializes advanced medical and protective technologies. CS Diagnostics Corp., a Wyoming-incorporated issuer trading on the OTCQB market, uses SEC filings to report material events, capital structure changes, and steps in its broader regulatory and growth strategy.
Among the key documents, investors can review Form 8-K filings such as the report describing the conversion of all outstanding Series B Preferred Stock held by affiliates CS Interpharm General Trading Co. LLC and CS Diagnostics Pharma GmbH into common shares. In that filing, the company explains how the conversion simplifies its equity capitalization, prepares for consolidated financial reporting, and aligns affiliate ownership with common shareholders. The filing also outlines the Securities Act exemptions relied upon and notes ongoing resale limitations under Rule 144 for affiliated holders.
CS Diagnostics Corp. has also discussed the submission of a registration statement draft for processing and future filing with the SEC, which it characterizes as an important step toward enhanced transparency, improved corporate governance, and expanded access to capital. As the company advances these efforts, investors can use this page to track new filings related to registration, periodic reporting, and additional material events.
Stock Titan’s platform pairs these filings with AI-powered summaries that highlight the main points of each document, helping readers understand how items such as preferred stock conversions, financing arrangements, and regulatory initiatives may affect CS Diagnostics Corp.’s structure and operations. Users can quickly scan filing types, dates, and topics, and then dive into full-text documents for deeper analysis of the company’s evolving disclosure record.
CS Diagnostics Corp. notifies the SEC it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 within the prescribed time and is requesting the 15‑calendar‑day extension under Rule 12b-25. The company states it needs additional time to complete financial statements and for its independent auditor to finish audit procedures. The registrant currently expects to file within the permitted 15‑day extension period and anticipates its results for the fiscal year ended December 31, 2025 will show a 25% increase in revenue versus the prior year.
CS Diagnostics Corp. filed Amendment No. 3 to a Form 10 registration under Section 12(g) to register its Common Stock, par value $0.00001 per share. The amendment incorporates an accompanying Information Statement (Exhibit 99.1) by reference and lists governance, license, distribution, asset purchase, valuation and product exhibits.
The filing cross-references business, risk factors, capitalization, security ownership, executive compensation, related-party transactions, legal proceedings and financial statements to the incorporated information statement.
CS Diagnostics Pharma GmbH filed an initial ownership report for CS Diagnostics Corp. (CSDX). The filing shows beneficial ownership of 104,507,800 shares of common stock held directly as of December 31, 2025, establishing the entity as a more than 10% shareholder.
CS Interpharm General Trading Co. LLC filed an initial ownership report showing a large stake in CS Diagnostics Corp. (CSDX). The filing reports beneficial ownership of 42,560,096 shares of CS Diagnostics common stock held directly as of December 31, 2025. No derivative securities such as options or warrants are listed in the report.
CS Interpharm LLC filed an initial ownership report for CS Diagnostics Corp., indicating beneficial ownership of 49,362,500 shares of Common Stock as of 12/31/2025. The filing classifies CS Interpharm LLC as a 10% owner with direct ownership of these shares.
CS Diagnostics Corp. filed Amendment No. 2 to its Form 10 to register its common stock under Section 12(g) of the Exchange Act. The filing covers common stock with a par value of $0.00001 per share and classifies the company as a smaller reporting company. Instead of repeating full disclosure, it incorporates by reference an information statement that includes sections on business, risk factors, management’s discussion and analysis, capitalization, security ownership, and executive compensation, along with audited financial statements. The exhibits list key corporate documents such as amended bylaws, an asset purchase agreement with CS Group, several license and distribution agreements related to MEDUSA products, and hydrogel-related valuation and study materials, providing investors with detailed background on the company’s operations and intellectual property arrangements.
CS Diagnostics Corp. reported its Q3 2025 results. For the nine months ended September 30, 2025, revenue was $94,200 versus $106,381 a year ago, while net income improved to $32,081 from $13,448, mainly on lower operating expenses. In Q3, the company posted a small net loss of $182 on revenue of $23,050.
Total assets were $499,431,013, driven by $499.4 million of intangible assets. Cash was $13 as of September 30, 2025, with accounts payable of $1,609. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing limited liquidity and the need for additional financing.
The capital structure included 137,340,200 common shares outstanding, 10 shares of Series A preferred, 19,992,575 of Series B preferred, and 4,000,000 of Series C preferred. The company noted pending civil actions and stated internal controls over disclosure were effective as of September 30, 2025.
CS Diagnostics Corp. (CSDX) completed a capital conversion, exchanging all outstanding Series B Preferred Stock held by affiliates into an aggregate 112,652,000 Common Shares on October 30, 2025.
The exchange was conducted under Securities Act exemptions Section 3(a)(9) (existing holders; no commission paid) and, alternatively, Section 4(a)(2). The company states the move aligns capital structures ahead of consolidated financial reporting for the fiscal year ending December 31, 2025.
Following the conversion, the affiliates now hold Common Shares and remain subject to Rule 144 resale limitations, including filing, volume, manner-of-sale, and current-public-information requirements.
CS Diagnostics Corp. (CSDX) reported a quarter marked by a large intangible-asset acquisition funded by equity. The balance sheet shows $499,400,000 of intangible assets and $504,163,629 of additional paid-in capital with an accumulated deficit of $(4,735,665). Cash flows show $(345) net cash used in operating activities, $(499,444,401) used in investing largely for intangible asset purchases, and $499,444,401 provided by financing reflecting equity infusions and issuance of preferred shares. The company issued Series B preferred shares (19,992,575 outstanding) and shows common shares of 137,340,200 outstanding as of June 30, 2025. Net income for the period is noted as $196, and year-to-date changes include shares issued in connection with asset acquisition.
Antonio Santoli reports beneficial ownership of 13,596,680 shares of CS Diagnostics Corp. common stock, representing 9.9% of the class. That total includes 3,800,000 shares held directly and 9,796,680 shares issuable on conversion of Series B preferred stock, but conversion is limited by a 9.9% conversion cap in the Series B Certificate of Designation. The filing states the reported ownership excludes any additional Series B shares that cannot be converted due to that cap and excludes securities held in entities where the reporting person lacks voting or dispositive power. The filing also notes the issuer’s Preferred A shares carry supervoting rights representing over 90% of voting power, and the reporting person certifies the position is not held to change or influence control.